Ligand Pharmaceuticals Incorporated Stock price

Equities

LGND

US53220K5048

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
73.1 USD +2.57% Intraday chart for Ligand Pharmaceuticals Incorporated -0.01% +2.35%
Sales 2024 * 137M Sales 2025 * 158M Capitalization 1.26B
Net income 2024 * 28M Net income 2025 * 52M EV / Sales 2024 * 9.19 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 8 x
P/E ratio 2024 *
43.7 x
P/E ratio 2025 *
25.6 x
Employees 58
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.16%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Ligand Pharmaceuticals Incorporated

1 day+2.57%
1 week-0.01%
Current month-7.88%
1 month-18.05%
3 months+1.13%
6 months+18.92%
Current year+2.35%
More quotes
1 week
68.25
Extreme 68.245
73.42
1 month
68.25
Extreme 68.245
85.06
Current year
67.53
Extreme 67.53
94.57
1 year
49.24
Extreme 49.24
94.57
3 years
49.24
Extreme 49.24
169.98
5 years
49.24
Extreme 49.24
219.75
10 years
41.99
Extreme 41.99
278.62
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 07-02-28
Director of Finance/CFO 53 22-10-31
President 49 15-08-05
Members of the board TitleAgeSince
Chairman 74 03-02-28
Director/Board Member 74 11-01-31
Director/Board Member 64 08-08-03
More insiders
Date Price Change Volume
24-03-28 73.1 +2.57% 109,733
24-03-27 71.27 +3.83% 191,807
24-03-26 68.64 -0.88% 107,915
24-03-25 69.25 -2.46% 107,055
24-03-22 71 -2.69% 67,489

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
73.1 USD
Average target price
116.8 USD
Spread / Average Target
+59.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Ligand Pharmaceuticals Incorporated - Nasdaq